Document is current

Article History

First Online: 10 September 2020

Declarations

:

: This study is part of a PhD programme funded by GlaxoSmithKline Biologicals SA and the ANRT (Association Nationale pour la Recherche et la Technologie, Paris, France).

: Hugo Arlegui was employed by the GSK group of companies at the time of the study in the framework of a PhD programme. Vincent Bauchau, Gaëlle Nachbaur and Nicolas Praet are employed by the GSK group of companies. GSK is the producer of some of the vaccines of interest in this review. Vincent Bauchau, Gaëlle Nachbaur and Nicolas Praet also hold shares in the GSK group of companies. Kaatje Bollaerts, Francesco Salvo and Bernard Bégaud declare no financial and non-financial relationships and activities and no conflicts of interest.

: Not applicable.

: Not applicable.

: Not applicable.

: All data generated and analysed during this study are included in this published article and its supplementary information files.

: Not applicable.

: All authors attest they meet the ICMJE criteria for authorship. All authors were involved in the conception of the study. Hugo Arlegui, Kaatje Bollaerts and Nicolas Praet participated in the collection and generation of the study data. Hugo Arlegui performed the study. All authors were involved in the analyses and interpretation of the data. All authors revised the manuscript critically for important intellectual content and gave final approval to submit for publication.